Anlon Healthcare Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 3 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹770 Cr

The company targets approximately 30% CAGR in revenue over the next 2-3 years. EBITDA margins are sustainable at 30-35%, with Anlon targeting around 35% and Apiqo around 30%; Bizotic expected to have similar margins (30-35% EBITDA) (Page 16, 7).

From Anlon Healthcare Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹14.3

Market Cap

₹770 Cr

P/E Ratio

24.4

How does Anlon Healthcare Ltd rank in Pharmaceuticals & Biotechnology?

Compare Anlon Healthcare Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Anlon Healthcare Ltd — Quarterly revenue & net profit

Revenue Net Profit

Jun 2024

Sep 2024

Dec 2024

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹36 Cr, net profit ₹5 Cr.

Full financials →

📊 Revenue & Sales Performance

→The company targets approximately 30% CAGR in revenue over the next 2-3 years.
→Revenue guidance for FY27 is INR 370-380 crore, considered a conservative estimate.
→By FY28, expected revenue is around INR 650-700 crore, potentially reaching up to INR 750 crore with expansions.
→Current capacity utilization is high (Anlon ~90%, Apiqo ~80%), prompting organic and greenfield expansions.
→Greenfield expansion at Anlon aims to triple capacity to around 1200-1300 metric tons annually, planned to go online by March 2027.
→Apiqo is also expanding by about 500-600 metric tons annually.
→Bizotic margins expected between 30-35% EBITDA; utilized around 50-55%, with potential for growth.
→CDMO model has a 3-4 year gestation from molecule development to revenue, with new molecules in validation.
→The robust order book for FY27 supports growth targets.

📈 Profitability & Margins

→EBITDA margins are sustainable at 30-35%, with Anlon targeting around 35% and Apiqo around 30%; Bizotic expected to have similar margins (30-35% EBITDA) (Page 16, 7).
→FY 26 revenue guidance stands at INR 170-180 crore; FY 27 guidance is INR 370-380 crore, considered conservative, with potential to exceed (Page 16, 14).
→Positive operating cash flow expected by FY 27, likely by H1 or latest H2 (Page 7).
→Organic greenfield expansions planned: Anlon capacity to triple (~1200-1300 MT p.a.), Apiqo expanding by ~500-600 MT p.a., contributing to revenue growth primarily post-FY 27 (Page 11, 5).
→Peak revenue projected around INR 700-750 crore by FY 27-28, driven by existing products and operational expansions (Page 11).
→Backward integration and strategic acquisitions (e.g., Bizotic) expected to support margin and top-line growth without significant cash outflow due to share swaps (Pages 16, 14).
→Working capital improvements and efficient fund management will support profitability and earnings growth (Page 6).

See what Anlon Healthcare Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Organic greenfield expansion planned for Anlon with CapEx of around INR 100-120 crore, targeting 1200-1300 metric tons per annum capacity, expected completion by March 2027; expansion execution to start April 2026.
→Apiqo also planning organic expansion with a similar scale, around 500-600 metric tons per annum capacity.
→Funding for CapEx: INR 40-50 crore from internal cash flow, remainder INR 50-60 crore via bank loans; peak debt-to-equity expected around 0.5-0.55.
→No major organic expansion currently planned for Bizotic.
→Strategic acquisitions: Apiqo and Bizotic to become 100% subsidiaries of Anlon, planned via share swap to avoid cash outflow.
→Exploring new greenfield projects in peptide manufacturing (e.g., for GLP-1 molecules and cosmetic peptides) as future strategic investments.
→Further product additions expected (6-7 new APIs) alongside capacity expansion over next financial years.

💰 Fundraising & Capital Structure

→For the planned greenfield expansion (~INR 100-120 Crores CapEx), the company expects to fund around INR 40-50 Crores from internal cash flow and the remaining INR 50-60 Crores through bank debt.
→Peak debt-to-equity ratio targeted is around 0.5 to 0.55, which is less than 1, considered reasonable.
→No immediate equity dilution is planned; the company aims to fund organic expansion primarily through internal accruals and bank loans.
→For acquisitions of subsidiaries (Apiqo and Bizotic), the company plans to use share swapping with existing shareholders, thus avoiding cash outflow and preventing cash crunch.
→Overall, moderate debt funding is planned with no major equity fundraising in the near term.

See what Anlon Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→Current order book for the remaining 1.5 quarters is around INR 30 Crores.
→For next financial year, the existing plant's capacity is fully booked with an order book of approximately INR 180-190 Crores.
→Apiqo Organics has a confirmed order book of around INR 125-130 Crores for the next year.
→Bizotic's order book details are pending until acquisition completion.
→No spare capacity available currently in existing plants for additional manufacturing beyond confirmed orders.
→Growth to INR 370-380 Crores in FY27 projected conservatively based on these orders and acquisitions.

Key Metrics

How does Anlon Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Anlon Healthcare Ltd

See full Pharmaceuticals & Biotechnology sector rankings

What AHCL's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

ONESOURCE (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
MANKIND (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
GLAND (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
SHILPAMED (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Anlon Healthcare Ltd Q3 FY26 results?

What is Anlon Healthcare Ltd share price analysis?

Anlon Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 24.4 with a market cap of ₹770 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anlon Healthcare Ltd planning capital expenditure?

Organic greenfield expansion planned for Anlon with CapEx of around INR 100-120 crore, targeting 1200-1300 metric tons per annum capacity, expected completion by March 2027; expansion execution to start April 2026.

Keep Anlon Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.